<DOC>
	<DOCNO>NCT01087554</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose combination vorinostat give combination either sirolimus , everolimus temsirolimus give patient advanced cancer . The safety drug combination also study .</brief_summary>
	<brief_title>Sirolimus Everolimus Temsirolimus Vorinostat Advanced Cancer</brief_title>
	<detailed_description>The Study Drugs : Vorinostat design prevent slow growth cancer cell block protein . Everolimus design stop cell divide . This may stop slow growth spread cancer cell . Temsirolimus design block protein call mTOR ( protein think cause cancer cell grow ) inside cancer cell . This may interfere growth spread cancer cell possibly kill . Sirolimus design block protein call mTOR inside cancer cell . This may interfere growth spread cancer cell possibly kill cancer cell . Study Drug Groups : If find eligible take part study , assign dose level vorinostat either sirolimus , everolimus , temsirolimus base join study . Up 9 dose level sirolimus vorinostat test . Up 3 dose level everolimus vorinostat test . Up 3 dose level temsirolimus vorinostat test . Three ( 3 ) 9 participant enrol dose level . The first group participant receive low dose level study drug combination . Each new group receive high dose group , intolerable side effect see . This continue high tolerable dose combination vorinostat sirolimus , everolimus , temsirolimus find . Once high tolerate dose combination find , 14 participant tumor type likely respond study drug combination receive study drug dose level . Study Drug Administration : Each study `` cycle '' 28 day . There 3 arm study , Arm A , Arm B , Arm C. You assign arm depend enroll study doctor think benefit . You take vorinostat either sirolimus ( Arm A ) , everolimus ( Arm B ) , temsirolimus ( Arm C ) . Everyday , take sirolimus mouth 1 time day . You take time day food cup ( 8 ounce ) water . If Arm A , Day 7 Cycle 1 , start take vorinostat mouth 1 time day . You take time day food cup ( 8 ounce ) water . If Arm B , take everolimus mouth time every day without food , swallow whole glass ( 8 ounce ) water . Do chew , break , crush everolimus . If Arm C , receive temsirolimus vein 30-60 minute Days 1 , 8 , 15 , 22 cycle . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : At every study visit , ask current health condition , drug may take , side effect . About Days 8 22 Cycle 1 : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . If enrol Arm B Hodgkin lymphoma , Days 8 28 Cycle 1 : - You needle tumor biopsy . This biopsy use DNA test check response study drug , describe `` Screening Tests '' section . - Blood ( 1 tablespoon ) drawn biomarker test . About Day 15 Cycle 1 , blood ( 2 teaspoon ) draw routine test . About Day 22 Cycles 2 beyond : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . Every 4 week , blood ( 1 teaspoon ) drawn urine collect pregnancy test able become pregnant . Every 8 week , x-ray , CT scan , MRI , and/or PET/CT check status disease . If study doctor think need , perform often . If enrol Arm B Hodgkin lymphoma , point disease appear get worse : - You needle tumor biopsy . This biopsy use DNA test check response study drug , describe `` Screening Tests '' section . - Blood ( 1 tablespoon ) drawn biomarker test . Length Study : You may continue take study drug long benefit . You take study experience intolerable side effect , study doctor think best interest , disease get bad . This investigational study . Sirolimus FDA approve commercially available anti-rejection drug kidney transplant recipient . Everolimus FDA-approved commercially available treatment pancreatic neuroendocrine tumor , subependymal giant cell astrocytoma , renal cell carcinoma . Temsirolimus FDA approve commercially available treatment renal cell carcinoma . Vorinostat FDA approve commercially available treatment cutaneous T-cell lymphoma . The combination drug investigational . Up 249 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Patients must histologicallyconfirmed metastatic locally advanced cancer fail respond standard therapy , progress despite standard therapy , standard therapy increase survival least three month exist 2 . There limit number prior treatment regimens 3 . Patients must prior cytotoxic chemotherapy least three week . For biologic target therapy , five half life three week , whichever short , last treatment first dose trial . 4 . Patients may receive palliative radiation therapy treatment protocol , provide measurable evaluable disease radiation field . Patients may receive palliative radiation therapy , need , 48 hour last dose investigational drug . In addition patient may enrol trial seven day follow palliative radiation . We closely monitor appearance radiation recall reaction . Hormonal therapy may continue patient treatment three month longer . 5 . ECOG performance status 03 6 . Patients must adequate organ marrow function define : absolute neutrophil count &gt; /= 1000uL , platelet &gt; /= 50,000uL , bilirubin &lt; /=2mg/dL ( exception may apply benign nonmalignant indirect hyperbilirubinemia Gilbert syndrome ) , ALT &lt; /= 2 x ULN &lt; /=5x ULN liver metastasis present , creatinine &lt; /= 2mg/dL 7 . As effect sirolimus everolimus temsirolimus vorinostat combination develop human fetus know , woman childbearing potential men must agree use adequate contraception ( abstinence ; hormonal barrier method birth control ) study least 3 month completion 8 . Female patient childbearing potential must negative serum urine pregnancy test within 7 day study enrollment . Nursing mother discontinue nurse 9 . Ability understand willingness sign write informed consent document 10 . Measurable evaluable disease 11 . Patient must able swallow pill 1 . Myocardial infarction within 3 month prior start treatment 2 . Concomitant use phenytoin , carbamazepine , barbiturate , rifampin , phenobarbital St. Johns wort , cyclosporine , diltiazem , ketoconazole discontinue possible . The list CYP3A4 inhibitor : http : //medicine.iupui.edu/clinpharm/ddis/clinicaltable/ 3 . Patient known hypersensitivity component study drug , analogue , drug similar chemical biologic composition 4 . Patient pregnant breastfeeding 5 . Major surgical procedure within 28 day day 1 therapy 6 . Use concurrent investigational agent anticancer agent except hormonal therapy outline inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamune</keyword>
	<keyword>mTOR Inhibitor</keyword>
	<keyword>Histone Deacetylase Inhibitor</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor</keyword>
	<keyword>Zortress</keyword>
	<keyword>RAD001</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>CCI-779</keyword>
	<keyword>Torisel</keyword>
</DOC>